中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(1): 110-115

Clinical effect of double plasma molecular adsorption system in treatment of patients with chronic liver failure in high-altitude areas

DOI: 10.12449/JCH20240119
  • 1.

    Critical Care Medical Center，General Hospital of Tibet Military Command，Lhasa 850000，China

  • 2.

    Department of Emergency，PLA Navy Characteristic Medical Center，Shanghai 200000，China

More Information
  • Corresponding author: SHEN Yuandi， dor_shen226@126.com （ORCID： 0000-0001-8466-4266）
  • Received Date: 2023-04-15
  • Accepted Date: 2023-05-19
  • Published Date: 2024-01-23
    Abstract
  •   Objective  To investigate the differences in clinical features and mortality rate between native patients with chronic liver failure （CHF） and migrated patients with CHF after treatment with double plasma molecular adsorption system （DPMAS） in high-altitude areas.  Methods  A total of 63 patients with CHF who received DPMAS treatment in the intensive care unit of General Hospital of Tibet Military Command from January 2016 to December 2021 were enrolled， and according to their history of residence in high-altitude areas， they were divided into native group with 29 patients and migrated group with 34 patients. The two groups were compared in terms of baseline data and clinical features before and after DPMAS treatment. The independent-samples t test was used for comparison of normally distributed continuous data between groups， and the paired t-test was used for comparison before and after treatment within each group； the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups， and the Wilcoxon signed rank sum test was used for comparison before and after treatment within each group； the chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to plot survival curves， and the Log-rank test was used for comparison of the risk of death.  Results  Compared with the native group， the migrated group had a significantly higher proportion of Chinese Han patients （χ2=41.729， P<0.001）， and compared with the migrated group， the native group had a significantly longer duration of the most recent continuous residence in high-altitude areas （Z=3.364， P<0.001）. Compared with the native group， the migrated group had significantly higher MELD score and incidence rates of hepatic encephalopathy， hepatorenal syndrome， and gastrointestinal bleeding （Z=2.318， χ2=6.903， 5.154， and 6.262， all P<0.05）. Both groups had significant changes in platelet count （PLT）， hemoglobin count （HGB）， alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， albumin， total bilirubin （TBil）， direct bilirubin （DBil）， lactate dehydrogenase （LDH）， creatinine （Cr）， and international normalized ratio （INR） after DPMAS treatment （all P<0.05）. Before DPMAS treatment， compared with the native group， the migrated group had significantly higher levels of ALT， AST， TBil， DBil， LDH， Cr， BUN， and INR （all P<0.05） and a significantly lower level of HGB （P<0.05）； after DPMAS treatment， compared with the native group， the migrated group had significantly greater reductions in PLT and HGB （both P<0.05） and still significantly higher levels of ALT， AST， TBil， DBil， LDH， BUN， and INR （all P<0.05）. The 60-day mortality rate of patients after DPMAS treatment was 52.5% （95% confidence interval ［CI］： 41.7 — 63.8） in the native group and 81.3% （95%CI： 77.9 — 85.6） in the migrated group. Compared with the native group （hazard ratio ［HR］=0.47， 95%CI： 0.23 — 0.95）， the migrated group had a significant increase in the risk of death on day 60 （HR=2.14， 95%CI： 1.06 — 4.32， P=0.039）.  Conclusion  Compared with the native patients with CHF in high-altitude areas， migrated patients have a higher degree of liver impairment， a lower degree of improvement in liver function after DPMAS treatment， and a higher mortality rate. Clinical medical staff need to pay more attention to migrated patients with CHF， so as to improve their survival rates.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [2]
    KARDASHIAN A, SERPER M, TERRAULT N, et al. Health disparities in chronic liver disease[J]. Hepatology, 2023, 77( 4): 1382- 1403. DOI: 10.1002/hep.32743.
    [3]
    PEREZ R, KORTGEN A, LEONHARDT J, et al. Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients[J]. Crit Care, 2022, 26( 1): 289. DOI: 10.1186/s13054-022-04163-1.
    [4]
    ALSHAMSI F, ALSHAMMARI K, BELLEY-COTE E, et al. Extracorporeal liver support in patients with liver failure: A systematic review and meta-analysis of randomized trials[J]. Intensive Care Med, 2020, 46( 1): 1- 16. DOI: 10.1007/s00134-019-05783-y.
    [5]
    VIANNA R. Current status of liver transplantation[J]. Gastroenterol Hepatol(N Y), 2021, 17( 2): 76- 78.
    [6]
    SALIBA F, BAÑARES R, LARSEN FS, et al. Artificial liver support in patients with liver failure: A modified DELPHI consensus of international experts[J]. Intensive Care Med, 2022, 48( 10): 1352- 1367. DOI: 10.1007/s00134-022-06802-1.
    [7]
    Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on clinical application of artificial liver and blood purification(2022 edition)[J]. J Clin Hepatol, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.

    中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.
    [8]
    LI J, LI J, CHAI M, et al. Comparison and analysis of prognostic factors of DPMAS combination with LPE and PE in early HBV- associated liver failure[J]. J Clin Exp Med, 2023, 22( 3): 257- 262. DOI: 10.3969/j.issn.1671-4695.2023.03.009.

    李瑾, 李静, 柴梅, 等. DPMAS联合LPE与PE治疗乙型肝炎病毒相关早期肝衰竭的疗效对比和预后影响因素分析[J]. 临床和实验医学杂志, 2023, 22( 3): 257- 262. DOI: 10.3969/j.issn.1671-4695.2023.03.009.
    [9]
    YANG JS, LIU J, QI LH, et al. The influence of two states of rapid entry to altitude and altitude acclimatization on myocardial injury index[J/CD]. Chin J Clin Lab Manag Electron Ed, 2020, 8( 4): 233- 236. DOI: 10.3877/cma.j.issn.2095-5820.2020.04.010.

    杨家树, 刘杰, 戚丽华, 等. 急进高原和高原习服两种状态对心肌损伤指标的影响[J/CD]. 中华临床实验室管理电子杂志, 2020, 8( 4): 233- 236. DOI: 10.3877/cma.j.issn.2095-5820.2020.04.010.
    [10]
    CHEN Y, LUO YJ. Research progress on the process and mechanism of intestinal flora regulating acclimatization at high altitude[J]. J Prev Med Chin People’s Liberation Army, 2020, 38( 4): 70- 72, 76. DOI: 10.13704/j.cnki.jyyx.2020.04.022.

    陈郁, 罗勇军. 肠道菌群调控高原习服适应过程及其机制研究进展[J]. 解放军预防医学杂志, 2020, 38( 4): 70- 72, 76. DOI: 10.13704/j.cnki.jyyx.2020.04.022.
    [11]
    YAN XM, WANG XH, SU YL, et al. Diagnosis and treatment of 38 cases of pulmonary tuberculosis complicated with puerperal infection and liver failure in plateau area[J]. J High Alt Med, 2021, 31( 2): 46- 50.

    颜小明, 王西红, 苏彦霖, 等. 高原地区肺结核合并产褥感染、肝衰竭38例诊治分析[J]. 高原医学杂志, 2021, 31( 2): 46- 50.
    [12]
    HORVATITS T, DROLZ A, TRAUNER M, et al. Liver injury and failure in critical illness[J]. Hepatology, 2019, 70( 6): 2204- 2215. DOI: 10.1002/hep.30824.
    [13]
    GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/S0140-6736(21)01374-X.
    [14]
    YAN Y, LYU CY, ZHOU XS, et al. The predictive value of liver failure-related etiology for clinical outcomes[J]. Chin Crit Care Med, 2022, 34( 2): 172- 177. DOI: 10.3760/cma.j.cn121430-20210705-01006.

    阎岩, 吕春燕, 周学士, 等. 肝衰竭相关病因学对临床结局的预测价值[J]. 中华危重病急救医学, 2022, 34( 2): 172- 177. DOI: 10.3760/cma.j.cn121430-20210705-01006.
    [15]
    YAN DD, YU HY, YU G, et al. Artificial liver support system combined with 131I for severe jaundice caused by Grave’s disease: A case report and literature review[J]. Fudan Univ J Med Sci, 2021, 48( 3): 418- 422. DOI: 10.3969/j.issn.1672-8467.2021.03.022.

    闫丹丹, 于浩泳, 俞岗, 等. 人工肝支持系统联合131I成功救治Grave’s病所致重度黄疸1例并文献复习[J]. 复旦学报(医学版), 2021, 48( 3): 418- 422. DOI: 10.3969/j.issn.1672-8467.2021.03.022.
    [16]
    SUN Q, LU X. Beijing children’s hospital affiliated to capital medical university: Using DPMAS technology to treat children with severe liver disease[J]. China Med Issues, 2022( 12): 12. DOI: 10.3760/cma.j.issn.1000-8039.2022.12.115.

    孙嫱, 卢曦. 首都医科大学附属北京儿童医院: 利用DPMAS技术救治重症肝病患儿[J]. 中华医学信息导报, 2022( 12): 12. DOI: 10.3760/cma.j.issn.1000-8039.2022.12.115.
    [17]
    ARROYO V, MOREAU R, JALAN R. Acute-on-chronic liver failure[J]. N Engl J Med, 2020, 382( 22): 2137- 2145. DOI: 10.1056/NEJMra1914900.
    [18]
    PAN JL, REN JY, LU XB, et al. Analysis of common operation alarm and influencing factors of DPMAS combined with PE in the treatment of liver failure[J]. J Xinjiang Med Univ, 2021, 44( 12): 1323- 1326. DOI: 10.3639/j.issn.1009-5551.2021.12.003.

    潘金良, 任洁雅, 鲁晓擘, 等. DPMAS联合PE治疗肝衰竭常见操作报警及影响因素分析[J]. 新疆医科大学学报, 2021, 44( 12): 1323- 1326. DOI: 10.3639/j.issn.1009-5551.2021.12.003.
    [19]
    LI J, LIU JD, WANG YY, et al. Clinical observation of PE combined with DPMAS sequential treatment of liver failure in end-stage liver disease[J]. J Air Force Med Univ, 2022, 43( 4): 325- 330. DOI: 10.13276/j.issn.2097-1656.2022.03.012.

    李静, 刘俊铎, 王允彦, 等. 血浆置换联合双重血浆分子吸附系统序贯治疗终末期肝病肝功能衰竭的临床观察[J]. 空军军医大学学报, 2022, 43( 4): 325- 330. DOI: 10.13276/j.issn.2097-1656.2022.03.012.
    [20]
    CAI YF, WANG ZH, CHENG SQ. A comparative study of three non-biological artificial liver models in the treatment of patients with acute-on-chronic liver failure[J/CD]. Chin J Liver Dis(Electronic Version), 2023, 15( 1): 47- 55. DOI: 10.3969/j.issn.1674-7380.2023.01.008.

    蔡毅峰, 王朝辉, 程书权. 三种非生物型人工肝模式治疗慢加急性肝衰竭患者的对比研究[J/CD]. 中国肝脏病杂志(电子版), 2023, 15( 1): 47- 55. DOI: 10.3969/j.issn.1674-7380.2023.01.008.
    [21]
    QIE HJ, LIU JT, WEN Y, et al. Effects and mechanism of exposure to high altitude environment on liver function in rats[J]. Med J Chin People’s Liberation Army, 2022, 47( 10): 961- 967. DOI: 10.11855/j.issn.0577-7402.2022.10.0961.

    且华吉, 刘江涛, 文艺, 等. 高原高海拔环境暴露对大鼠肝脏功能的影响及其机制[J]. 解放军医学杂志, 2022, 47( 10): 961- 967. DOI: 10.11855/j.issn.0577-7402.2022.10.0961.
    [22]
    FENG H, JIA NY, LIU Y, et al. Correlation offatty liver with hypobaric hypoxia in plateau encamping soldiers for short time[J]. Mil Med J Southeast China, 2016, 18( 3): 259- 261. DOI: 10.3969/j.issn.1672-271X.2016.03.011.

    丰惠, 贾宁阳, 刘燕, 等. 高原驻训官兵肝脏脂肪变性与缺氧等关系探讨[J]. 东南国防医药, 2016, 18( 3): 259- 261. DOI: 10.3969/j.issn.1672-271X.2016.03.011.
    [23]
    WANG Z, ZHANG PL, YANG FM. Research progress on the mechanism of hypoxic liver injury and the changes of coagulation factor levels[J]. Chin J Gen Pract, 2021, 19( 10): 1733- 1736. DOI: 10.16766/j.cnki.issn.1674-4152.002154.

    王珍, 张培莉, 杨发满. 缺氧性肝损伤机制及其凝血因子水平变化的研究进展[J]. 中华全科医学, 2021, 19( 10): 1733- 1736. DOI: 10.16766/j.cnki.issn.1674-4152.002154.
    [24]
    XIAO R, TIAN H, HU XD, et al. Comparison of sonographic measurement values of liver and portal vein among plateau native Tibetan nationality, plateau migrated Han nationality and plain native Han nationality[J]. Chongqing Med, 2018, 47( 34): 4387- 4389. DOI: 10.3696/j.issn.1671-8348.2018.34.016.

    肖蓉, 田虹, 胡晓丹, 等. 高原世居藏族、高原移居汉族和平原世居汉族肝脏及门静脉超声测量值比较[J]. 重庆医学, 2018, 47( 34): 4387- 4389. DOI: 10.3696/j.issn.1671-8348.2018.34.016.
    [25]
    SONG Z, ZHANG AX, LUO J, et al. Prevalence of high-altitude polycythemia and hyperuricemia and risk factors for hyperuricemia in high-altitude immigrants[J]. High Alt Med Biol, 2023, 24( 2): 132- 138. DOI: 10.1089/ham.2022.0133.
    [26]
    NAKAO M, NAKAYAMA N, UCHIDA Y, et al. Nationwide survey for acute liver failure and late-onset hepatic failure in Japan[J]. J Gastroenterol, 2018, 53( 6): 752- 769. DOI: 10.1007/s00535-017-1394-2.
    [27]
    MA XY, MA JP, YANG YJ. Epidemic characteristics of hepatitis B patients from the plateau region of Qianghai, 2017-2019[J]. Pract Prev Med, 2021, 28( 12): 1521- 1523. DOI: 10.3969/j.issn.1006-3110.2021.12.029.

    马秀英, 马金鹏, 杨永娟. 2017—2019年青海高原地区乙肝人群流行特征[J]. 实用预防医学, 2021, 28( 12): 1521- 1523. DOI: 10.3969/j.issn.1006-3110.2021.12.029.
    [28]
    LEI Y, LIANG YL, ZHANG XM, et al. Alternating therapeutic plasma exchange(TPE) with double plasma molecular adsorption system(DPMAS) for the treatment of fulminant hepatic failure(FHF)[J]. Clin Case Rep, 2021, 9( 12): e05220. DOI: 10.1002/ccr3.5220.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (249) PDF downloads(42) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return